linkedin post 2013-06-10 05:46:08

Uncategorized
BIOLOGICAL DRUGS will be at least 50% of new drug approvals in coming years. Small molecule drugs are having a tough time keeping up with this tsunami of very effective monoclonals. Those Pharma groups that have been slow to enter this brave new age of biologicals can only catch up by acquisition. And that will be costly. http://lnkd.in/q5xemV View in LinkedIn
Read More

linkedin post 2013-06-10 05:32:30

Uncategorized
FABULOUS REPURPOSING STUDY which is in collaboration with Minoryx, an award winning Spanish company on the fast-track to break out of the box. The PI in this study is a brilliant physician-researcher and the data are compelling. Repurposing of drugs for new indications is a strategy that de-risks a clinical program because the drug has already extensive exposure in man and has undergone safety and toxicity testing, a big reason for a No-Go in drug development. Glitazones have a very interesting MOA and for this reason, despite warning labels, if used at low doses, may be very valuable. http://www.sciencedaily.com/releases/2013/06/130607222510.htm View in LinkedIn
Read More

linkedin post 2013-06-09 09:10:57

Uncategorized
MY DINO TURD is a cross section of a 3 pound fossilized dinosaur poop that is my favorite paperweight. On the cross-section of what appears to have been a smooth oval, measuring 5 inches by 3 inches, are symmetrical bones and teeth fragments, that are clearly visible. This ancient excrement is a source of immense pleasure, and an invaluable defense against unexpected intruders. View in LinkedIn
Read More